Forecasting individual pharmacokinetics

  title={Forecasting individual pharmacokinetics},
  author={Lewis B. Sheiner and Stuart L. Beal and Barr Rosenberg and Vinay V. Marathe},
  journal={Clinical Pharmacology \& Therapeutics},
Often drug dosage may be chosen rationally by use of plasma concentration (CP) as the “therapeutic” end point. The ability to accurately forecast the CP resulting from a dosage regimen is central to choosing that regimen. Traditionally forecasting has been attempted only by accounting for known influences on pharmacokinetics, such as sex, age, and renal disease. One must also adjust for previously observed CPs. Herein, we discuss and explain an approach to both of these tasks, mainly focusing… 

Antimicrobial breakpoint estimation accounting for variability in pharmacokinetics

Compared to traditional methods, the weighted AUC approach gives a more powerful PK/PD link and reveals, through examples, interesting issues about the uniqueness of therapeutic outcome indices and antibiotic resistance problems.

Therapeutic Drug Monitoring of Imatinib

Clinical interpretation of randomly measured imatinib plasma concentrations can be assisted by Bayesian TDM, and classical Bayesian MAP estimation can be applied even without consideration of the correlation between pharmacokinetic parameters.

Population Pharmacokinetics Theory and Clinical Application

A move towards the adoption of population pharmacokinetics as a routine procedure during drug development and, where appropriate, proceed to the establishment of control systems based on Bayesian feedback is encouraged.

Predicting individual phenytoin dosage

This paper compares the Bayesian method as applied to phenytoin to two other prediction methods (and a baseline, nonfeedback one) and concludes that the superiority of the latter may be a general phenomenon.

The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods.

The standard approaches are discussed and illustrated (using nondeficient data) in order to introduce subsequent papers in which alternative data analysis methods for population parameter estimation are defined, discussed, and compared.

Evaluation of single-point phenytoin dosage prediction methods in pediatric patients.

The use of method B is recommended to make routine PHT dosage adjustments in pediatric patients when only one dose and one concentration are available, and mean prediction error, mean absolute error (MAE), and root mean squared error (RMSE) were separately calculated for each method.

Application of Population Pharmacokinetic Modeling for Individualized Infliximab Dosing Strategies in Crohn Disease

Individualized IFX dosing strategies in children with CD will be critical to consistently achieve trough concentrations associated with optimal outcomes, and a one-size-fits-all approach to dosing is inadequate.

Population Pharmacokinetic Models

Using a new nonparametric expectation maximisation (NPEM) population modelling program and retrospective data from 129 preterm infants who received gentamicin in their own clinical setting, 2 population models were developed and the median proved a better measure of central tendency.

Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: evaluation of doxepin and imipramine--new data and review.

At doses approaching the upper range recommended for the treatment of depression, Cpss appear to approach, in at least a few individuals, the maximum metabolic capacity of the patient, leading to greater-than-expected increases in concentrations for a given dosage increment.



Modelling of individual pharmacokinetics for computer-aided drug dosage.

Individualization of phenytoin dosage regimens

It was concluded that the use of individual pharmacokinetic parameters is practical and is also superior to the nomogram.

Determination of therapeutic and toxic serum digoxin concentrations by radioimmunoassay.

A sensitive (0.2 ng per milliliter), precise, and specific radioimmunoassay for serum digoxin concentration has been developed, and may provide useful information to the clinician faced with the difficult problem of evaluating his patient's state of digitalization.

Reducation of digitalis toxicity by computer-assisted glycoside dosage regimens.

Computer-assisted dosage regimens of digitalis leaf, digitoxin, digoxin, and deslanoside (Cedilanid-D®) have reduced the frequency of adverse reactions to such glycosides from 35% to 12% in mice treated with these drugs.

Computer simulation in the service of chemotherapy.

Digitalis assay and its clinical application.

  • S. Oparil
  • Medicine
    The Medical clinics of North America
  • 1976

Clinical pharmacokinetics : The use of plasma concentrations of drugs

    Theophylline therapy: nomogram guidelines

    • Ann Intern Med
    • 1977